Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives.
about
Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional studyLiver tumors in children with metabolic disordersNutrition and metabolism in hepatocellular carcinomaTreating iron overload in patients with non-transfusion-dependent thalassemiaPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesEffects of strain and age on hepatic gene expression profiles in murine models of HFE-associated hereditary hemochromatosisEvidence for the Influence of the Iron Regulatory MHC Class I Molecule HFE on Tumor Progression in Experimental Models and Clinical PopulationsAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma markerHereditary hemochromatosis: a neglected diagnosis in orthopedics: a series of 7 patients with ankle arthritis, and a review of the literatureThe diagnosis and management of hereditary haemochromatosis.Iron and cancer: more ore to be mined.Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.Non-viral causes of hepatocellular carcinoma.Intracellular iron transport and storage: from molecular mechanisms to health implications.Prevention of mutation, cancer, and other age-associated diseases by optimizing micronutrient intake.Recent insights on risk factors of hepatocellular carcinomaHepatocellular carcinoma in thalassemia: A critical reviewIron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function.Epidemiology of primary and secondary liver cancers.Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triageHepatocellular carcinoma in patients with autoimmune hepatitis.Non-viral factors contributing to hepatocellular carcinoma.Hepatic iron overload and hepatocellular carcinoma.HFE genotyping in patients with elevated serum iron indices and liver diseasesHereditary pancreatic and hepatobiliary cancersHFE gene mutations in susceptibility to childhood leukemia: HuGE review.Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway.Iron intake and markers of iron status and risk of Barrett's esophagus and esophageal adenocarcinomaDoes hemochromatosis predispose to celiac disease? A study of 29,096 celiac disease patients.Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.The heme-p53 interaction: Linking iron metabolism to p53 signaling and tumorigenesis.Pathological investigation of oxidative stress in the post-genomic era.Cellular iron metabolism in prognosis and therapy of breast cancer.Hemochromatosis gene status as a risk factor for Barrett's esophagusIron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study.Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversiesIndications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX).A comparison between whites and blacks with severe multi-organ iron overload identified in 16,152 autopsies.Epidemiology and management of hepatocellular carcinoma.
P2860
Q24811285-95106D6B-6C85-442E-8320-DAD60EDD6B86Q26770292-62565FD8-BD09-4A02-9A0D-FAA0BB42F1C2Q26862862-AACA6A14-1A7F-4C05-9B3A-FB9FF474339DQ27009463-E9DC49FD-F7AA-478F-B7B4-EB9640A14AEAQ28272678-F17384E9-895F-4DCC-9C07-2A5B4C54BA6DQ28383110-5F613B7C-D925-4979-A0C5-5A40677E174EQ28383815-33ED8C26-535D-4B6E-AF89-86712A806CA4Q30479629-18561822-08C8-459D-87CD-D26129C5A4D7Q31113966-3528D6F5-0418-43A6-8C49-67C382BAA164Q33660053-72179F71-B588-47D2-A110-D7A4FAC084D0Q33677583-0889D090-59FD-4C66-9A92-C3A51284F161Q33677592-EFFA04CF-60C9-4D68-A984-E55F87C5FAA6Q33866448-2CB45C6F-09ED-40A2-9A49-36BC14420716Q34041381-39702595-8BFF-4E6A-AB50-05791ACFFFE1Q34100135-CFE4B840-A68A-4B93-8760-6323E7745239Q34155788-210B931F-4E15-4D30-88E9-251DCC58DE43Q34391482-FAAC0469-61E3-4B54-B264-D20EC8E0994BQ34391592-83AB17DF-9D35-43D9-A0EB-515E94651F79Q34449959-B0CB929C-724D-4127-8AA0-F458AEE49FF1Q34563350-072E931C-6EAD-4143-A4CC-83B0B622658DQ34581373-8145486B-E557-4F26-A4D8-7C4100CEC991Q34604173-3764F90F-6EBE-413B-A9C7-F1A6E2FB5656Q34653639-B80A0873-7342-4FB9-956A-56E9DCA751D4Q34661782-40513079-F841-434B-A1CB-3D7D9753618EQ35025914-448BEC9D-A40D-4151-9120-E7D46E254D91Q35692230-5C918284-B0BD-42A9-B93E-46CBDB8A6C73Q36073704-BA8301F2-1E74-48EA-BCC3-E7D5B6BABA86Q36202895-DF5AD942-7C15-4FEE-A2F4-2B59AEFE467CQ36225518-1412E5E2-7D1F-4CCD-A67E-F57DAEE77B9DQ36622325-D2215AB8-F7D5-4335-AAFE-476B5BA53FEAQ36699256-4D5DF75D-4570-4F36-9A94-5F10BA0A8D7DQ36836299-1853A0E5-C45A-4AF4-B726-A431EEEA30C9Q36870107-2ED74934-ADF3-46A8-B3DD-C6E25470B542Q37077422-569813D0-EB91-4063-AED6-89F4A1E1DE93Q37163173-B676539A-BCA6-4D90-B3E4-A6CFF20B90EBQ37163598-DBC17609-D883-4B5B-8A0A-5F7720087011Q37266376-C49B4B3F-D480-4BED-879A-7730AD01D9A9Q37314134-2F342969-EB15-433A-8546-A9893FA68DBAQ37420938-06AA076D-3B90-4A2A-81C5-D02A1D571C3AQ37629940-54206821-4DE0-4661-B7E3-830D26459952
P2860
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cancer risk in patients with h ...... their first-degree relatives.
@en
Cancer risk in patients with h ...... their first-degree relatives.
@nl
type
label
Cancer risk in patients with h ...... their first-degree relatives.
@en
Cancer risk in patients with h ...... their first-degree relatives.
@nl
prefLabel
Cancer risk in patients with h ...... their first-degree relatives.
@en
Cancer risk in patients with h ...... their first-degree relatives.
@nl
P2093
P1433
P1476
Cancer risk in patients with h ...... their first-degree relatives.
@en
P2093
Hanna Sandberg-Gertzén
Johan Askling
Lena Brandt
Maria Elmberg
Rolf Hultcrantz
Rolf Olsson
Sigvard Olsson
Stefan Lindgren
P304
P356
10.1053/J.GASTRO.2003.09.035
P407
P577
2003-12-01T00:00:00Z